Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes

(2020) Paolo Pozzilli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

(2019) Michael J. Haller et al.   DIABETES

Persistent C‐peptide is associated with reduced hypoglycaemia but not HbA 1c in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?

(2019) S. M. Marren et al.   DIABETIC MEDICINE

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

(2019) Kevan C. Herold et al.   NEW ENGLAND JOURNAL OF MEDICINE

WITHDRAWN: IDF Diabetes Atlas: Worldwide Estimates of Incidence, Prevalence and Mortality of Type 1 Diabetes in Children and Adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

(2019) Christopher C. Patterson et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta‐cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes

(2019) Wei Wang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

An overview of GLP-1 agonists and recent cardiovascular outcomes trials

(2019) Kelsey H Sheahan et al.   POSTGRADUATE MEDICAL JOURNAL

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

(2018) Daniel J. Drucker   Cell Metabolism

Impact of C-Peptide Status on the Response of Glucagon and Endogenous Glucose Production to Induced Hypoglycemia in T1DM

(2018) Sabine Zenz et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes

(2017) Anna K. Rydén et al.   JOURNAL OF AUTOIMMUNITY

Type 1 diabetes in older adults: Comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries

(2016) Ruth S. Weinstock et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial

(2016) Stanislav Ignatenko et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients

(2015) Ricardo C. Ferreira et al.   DIABETOLOGIA

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

(2015) Mark R. Rigby et al.   JOURNAL OF CLINICAL INVESTIGATION

Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study

(2014) Kamlesh Khunti et al.   DIABETES CARE

GLP-1 Analog Liraglutide Enhances Proinsulin Processing in Pancreatic β-Cells via a PKA-Dependent Pathway

(2014) Liang Wang et al.   ENDOCRINOLOGY

Trials in type 1 diabetes: Antigen-specific therapies

(2013) Ken T. Coppieters et al.   CLINICAL IMMUNOLOGY

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

(2013) E. R. Seaquist et al.   DIABETES CARE

Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes

(2013) Jing Lu Kroll et al.   JOURNAL OF CLINICAL VIROLOGY

Glucagon-Like Peptide-1 Protects Human Islets against Cytokine-Mediated β-Cell Dysfunction and Death: A Proteomic Study of the Pathways Involved

(2013) Dieter Rondas et al.   JOURNAL OF PROTEOME RESEARCH

Non-antigenic and antigenic interventions in type 1 diabetes

(2013) Anna KE Rydén et al.   Human Vaccines & Immunotherapeutics

Interleukin-21 Receptor-Mediated Signals Control Autoreactive T Cell Infiltration in Pancreatic Islets

(2012) Tom L. Van Belle et al.   IMMUNITY

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

(2009) B. Keymeulen et al.   BLOOD

Interleukin-21 Is Required for the Development of Type 1 Diabetes in NOD Mice

(2009) A. P.R. Sutherland et al.   DIABETES

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-21 signaling is critical for the development of type I diabetes in the NOD mouse

(2008) R. Spolski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA